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Abstract
Schizophrenia is a chronic and severe mental illness which frequently leads to
substantial lifelong disability. The past five years have seen major progress in
our understanding of the complex genetic architecture of this disorder. Two
major barriers to understanding the core biological processes that underlie
schizophrenia and developing better interventions are (1) the absence of
etiologically defined biomarkers and (2) the clinical and genetic heterogeneity
of the disorder. Here, we review recent advances that have led to changes in
our understanding of risk factors and mechanisms involved in the development
of schizophrenia. In particular, mechanistic and clinically oriented approaches
have now converged on a focus on disruptions in early neurodevelopment and
synaptic plasticity as being critical for both understanding trajectories and
intervening to change them. Translating these new findings into treatments that
substantively change the lives of patients is the next major challenge for the
field.
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Introduction
Schizophrenia is a severe and highly disabling chronic mental 
illness involving disordered thought and perception. Its 
characteristic onset in late adolescence/early adulthood is often 
associated with a marked, lifelong impact on social and role 
functioning. At the same time, there is a wealth of evidence 
from epidemiologic birth cohort and retrospective studies that 
at least a proportion of individuals who ultimately develop 
schizophrenia have more subtle deficits in cognitive, social- 
affective, motor, and language development in early childhood, 
long before the onset of overt illness. This would suggest 
that (1) onset of overt symptoms is a “late stage” of illness, 
providing a window of opportunity to intervene if those at risk can 
be accurately identified, and (2) schizophrenia, despite its later 
age at onset, may be considered a disorder of disrupted 
neurodevelopment.
In the past decade, significant advances in our understanding of 
the genetic architecture of schizophrenia have confirmed intui-
tions that convergent biological pathways across disparate genetic 
risk factors implicate genes involved in synaptic plasticity and 
neuronal development. Yet, despite this impressive body of new 
knowledge regarding risk genes for schizophrenia, we still have 
a very incomplete understanding of mechanism. Two major 
obstacles to elucidating the core biological processes that 
underlie schizophrenia are (1) the absence of objective biomar-
kers and (2) the clinical and genetic heterogeneity of the 
disorder1. These also impede our ability to develop better and 
more mechanistically informed interventions.
Here, we will discuss the major discoveries of the past few 
years and relevant clinical advances. The emerging framework 
is one of disrupted neurodevelopment involving both early, 
subtle anomalies and progressive maturational disturbances, 
namely accelerated gray matter loss in regions critical for higher- 
order cognition2. Studies of youth at clinical high risk (CHR) for 
developing psychosis have greatly informed our understanding 
of risk factors, the importance of early intervention, and poten-
tial mechanisms proximal to illness onset, but there are also 
challenges. In particular, potential bias in recruitment strate-
gies and late identification of at-risk individuals pose potential 
limitations3. As such, we need alternative approaches to identify 
those at highest risk earlier in development. As we will discuss 
in detail below, examining convergence of clinically defined risk 
with rare genetic variants that are highly penetrant for illness can 
better advance mechanistic understanding of psychosis risk. 
However, key challenges for the field remain, namely how we 
translate scientific advances into real improvements in clinical 
care and disease prognosis.
The genetic architecture of schizophrenia
For many years, it was known, based on consistent evidence from 
twin and family studies, that schizophrenia is highly heritable4–7. 
As such, there was a widely held view that understanding the 
genetics of schizophrenia might provide a window into the disease 
biology. Given the prevalence of schizophrenia (about 1% in the 
general population) and its genetic inheritance pattern, investigators 
proposed a “common-disease, common-allele” model8, in which 
illness results from the cumulative effect of multiple common 
alleles. Yet, even in studies of thousands of individuals, no 
genome-wide significant risk variants had been identified. 
However, karyotypic abnormalities had been detected in affected 
individuals or families9, suggesting the possibility of some major 
mutational causes of schizophrenia. The advent of microar-
ray-based methodology recently enabled the detection of much 
smaller structural genetic events. In 2008, our understanding of 
the genetic architecture changed dramatically with the findings 
of Walsh et al.10, who reported that some mutations predisposing 
to schizophrenia are highly penetrant (odds ratios range from 
2 to 30), individually rare, and evolutionarily recent. In rapid 
succession, several larger consortia studies confirmed and repli-
cated these findings, revealing that submicroscopic copy number 
variations (CNVs)—including recurrent deletions at 1q21.11, 
15q11.3, 22q11.2, and the neurexin 1 locus at 2p16.3—are 
associated with greatly increased risk for psychosis as well as 
other developmental neuropsychiatric disorders and intellectual 
disability11–13. These CNVs occur disproportionately in loci con-
taining genes involved in synaptic function and neurodevelop-
ment, including neuregulin and glutamate pathways, as well as the 
post-synaptic density, including the activity-regulated cytoskeleton 
(ARC) protein complex, which localizes to NMDAR (N-methyl-
D-aspartate receptor)-activated synapses and plays a role in 
plasticity-induced cytoskeleton changes14. Yet, collectively, 
these risk loci are carried by less than 2.5% of patients and thus 
do not explain the majority of cases of schizophrenia. In 2014, 
in a genome-wide association study (GWAS) of about 36,000 
patients and over 100,000 controls, the Psychiatric Genomics 
Consortium15 reported the very first set of genome-wide 
significant findings for common schizophrenia risk variants. This 
study implicated over 100 loci but all with individually small 
effect sizes. These risk variants were enriched for brain-expressed 
genes and for genes relevant to synaptic plasticity and immune 
function, particularly within the major histocompatibility 
complex (MHC) region. Subsequently, Sekar et al.16 demonstrated 
an association between risk for schizophrenia and genetic vari-
ation that alters expression of particular forms of complement 
component 4 (C4), part of the innate immune system. Impor-
tantly, the authors linked these genetic findings to schizophrenia 
pathophysiology for the first time, as they showed that loss of C4 
resulted in reduced post-natal synaptic pruning in a mouse model. 
Given that increased expression of CA4a is associated with greater 
risk of schizophrenia, these findings support the long-standing 
hypothesis that disrupted synaptic refinement (that is, perhaps 
overly aggressive synaptic pruning) in adolescence plays a key 
role in disease etiology17.
This rapid progress has continued with advances in data sharing, 
meta-analytic methods, and hence the publication of ever-
larger GWASs and exome sequencing studies. Across the allelic 
frequency spectrum, this recent work consistently implicates 
biological pathways involved in synaptic functions; indeed, 
Genovese et al.18 recently found that potentially synaptic genes 
appear to explain more than 70% of the exome enrichment in 
damaging ultra-rare variants contributing to schizophrenia. Syn-
aptic plasticity, while critical for learning and memory across the 
life span, is also critically involved in development, as it plays a 
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key role in organizing neurons into finely tuned circuits required 
for a mature brain2.
The individually small but cumulative effects of multiple risk 
genes found in GWASs led to the development and increasing 
popularity of leveraging polygenic risk scores (PRS) for 
schizophrenia (i.e. calculating the total number of inde-
pendent risk alleles, weighted by their effect sizes on 
disease, carried by an individual)19,20. The schizophrenia PRS has 
become an important potential “summary measure” for use in 
assessing risk and possibly future stratification in clinical trials21.
Nevertheless, given that no single common variant has an 
individually large effect, rare damaging variants and recurrent 
CNVs like the 22q11.2 microdeletion that are highly penetrant 
for psychosis may offer a clearer path toward mechanistic 
understanding (Figure 1). Moreover, as such mutations can be 
detected very early in development (even in utero), they offer a 
unique opportunity for prospective study of neurodevelopmental 
influences on the evolution of psychosis, long before disease-related 
processes begin to unfold. As sample sizes increase, additional 
rare variants are likely to be discovered via sequencing 
methodologies; these genes are likely to cluster in similar path-
ways as the known risk variants but may also suggest additional 
biological processes.
Recently, Tansey et al.22 identified a way in which these differ-
ing genetic mechanisms may converge: specifically, relative to 
controls, individuals with schizophrenia with known pathogenic 
CNVs also have an excess burden of common risk alleles. This 
finding supports a polygenic threshold model of schizophrenia, 
meaning that multiple risk variants may converge to reach a 
“risk threshold”, in contrast to an extreme heterogeneity model in 
which carriers of certain high-penetrance mutations form distinct 
subgroups. Importantly, these results support the notion that studies 
of rare variation may reveal pathophysiological mechanisms 
relevant to the broader population.
Overall, these large-scale genomic studies suggest that (1) 
schizophrenia is highly polygenic, involving hundreds to thou-
sands of genes, and both common and rare variants confer 
risk; (2) schizophrenia risk variants are enriched for biological 
Figure 1. Convergence of rare and common genetic variation on disrupted synaptic function and neurodevelopmental processes. 
Convergence of rare and common genetic variation on disrupted synaptic function and neurodevelopmental processes. Top right-hand panel 
reprinted by permission from: Springer Nature. Nature. Biological insights from 108 schizophrenia-associated genetic loci. Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, Stephan Ripke, Benjamin M. Neale, Aiden Corvin, James T. R. Walters et al., 2014.
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pathways that include synaptic development and plasticity 
as well as glutamatergic signaling23; and (3) these risk variants 
partially overlap with those implicated in other developmental 
disorders, notably autism spectrum disorder and intellectual/ 
developmental disability. Collectively, these recent findings 
support an emerging framework of lifelong biological vulnerability, 
which sets the stage for events during adolescence—includ-
ing abnormal pruning and increased cortical dysconnectivity— 
that lead to neural disruption and clinical symptoms.
Nevertheless, there is considerable variability in course and 
outcome. Although psychosis onset is most common in late 
adolescence or early adulthood, some patients experience their 
first psychotic episode as early as childhood or after 40 years of 
age. Similarly, subsets of patients show a rapid onset of cognitive 
and functional decline in adolescence or early adulthood whereas 
others show poor cognitive function much earlier in life. This 
clinical variability may be related to variability in genetic pro-
files and heterogeneous molecular pathways: in particular, one 
hypothesis is that a relatively greater “rare variant” contribution 
may be present in patients with both schizophrenia and cognitive 
impairment and may characterize those patients with poorer 
premorbid function; this possibility is partially supported by 
Singh et al.24, who recently found that the burden of rare, 
damaging variants is greater in patients with both schizophrenia 
and intellectual disability. However, this excess of rare, 
loss-of-function intolerant variants relative to controls is also 
seen in patients with schizophrenia who do not have intellectual 
disability, suggesting a “risk continuum”.
Early identification and intervention: psychosis as a 
late stage
In parallel to these large-scale genetics discoveries, clinical 
advances over the past decade have focused on earlier identifica-
tion and intervention, based on increasing evidence that reducing 
the duration of untreated psychosis results in better outcome, in 
terms of treatment response and both short- and longer-term role 
functioning25–27. Indeed, beginning in the mid-1990s, diagnostic 
criteria aimed at identifying individuals at high risk for immi-
nent development of psychosis were established and applied in a 
number of clinical research studies28,29. This work is founded on 
the well-established “clinical staging” principle in medicine, which 
has shown that, for a number of common diseases, the invasiveness 
of the intervention scales with its timing, such that more benign 
(and low-cost) treatments are likely to be effective in the very early, 
“pre-onset” stages. Beginning with the implementation of early 
detection programs in Australia30,31, this concept rapidly expanded 
to Europe and the US. Overall, rates of conversion to overt 
psychosis in this identified CHR group range from 20 to 40% 
during the first three years after ascertainment28,32. Among those 
who do not develop a psychotic disorder, outcomes are highly 
variable; about one third continue to display significant subthresh-
old symptoms and functional impairment, and one third show 
symptomatic remission33. Lower levels of negative mood and 
anxiety symptoms were associated with greater likelihood of both 
symptomatic and functional recovery.
A prospective multisite study, the North American Prodromal 
Longitudinal (NAPLS) consortium34, has been prospectively 
following CHR youth with repeated clinical, cognitive, and imaging 
and blood biomarker assays and aims to improve our ability to 
predict conversion to psychosis so that preventive interventions 
can be offered to those who most need them. Recently, the NAPLS 
consortium found a set of replicable clinical and cognitive risk 
factors that predicted risk of conversion to psychosis on an indi-
vidual basis: specifically, higher levels of unusual thought content 
and suspiciousness, poorer verbal learning and memory and 
information-processing speed, decline in social functioning, and 
younger age at baseline each contributed to individual risk for 
psychosis35. The multivariate model achieved an overall accuracy 
that was comparable to that of individual prediction models for car-
diovascular disease and cancer recurrence and was validated in an 
independent external data set36. Based on these results, a web-based 
risk prediction tool was made available for predicting individual 
risk of conversion to psychosis in clinically ascertained cohorts.
Additionally, an important potential imaging biomarker for risk 
prediction emerged from this multisite project, which found 
that those who converted to psychosis over the follow-up period 
showed a significantly greater rate of gray matter loss than those 
who were symptomatic at baseline but did not convert37. Gray 
matter loss was correlated with pro-inflammatory cytokines in 
plasma, suggesting a possible neuro-inflammatory mechanism. 
The discovery that variation in C4—part of the innate immune 
system—is causally involved in synaptic pruning16 suggests a 
possible mechanistic basis for this finding. Future studies includ-
ing the addition of imaging and potentially genetic biomarkers 
(for example, high polygenic risk for schizophrenia) to the 
calculator model are warranted to determine whether such factors 
account for additional variance.
Despite these advances, the proposal to include “psychosis risk 
syndrome” as a diagnostic category in the fifth edition of the 
Diagnostic and Statistical Manual of Mental Disorders remained 
controversial and ultimately was not included. Instead, “attenuated 
psychosis syndrome” was included as a “condition for 
further study”. Some of the reservations regarding its inclusion 
are that (1) specialized CHR services detect a only small minor-
ity of those who will ultimately develop psychosis, suggesting 
problems with ascertainment which may bias our understanding of 
mechanistic pathways to psychosis3, (2) a substantial portion 
of individuals identified as CHR convert to psychosis shortly 
after ascertainment, and thus may be too advanced in the illness 
process to alter the trajectory, and (3) the majority of individuals 
who meet CHR criteria do not go on to develop a full-blown 
psychotic disorder28; thus, the “psychosis risk syndrome” label 
may imply a greater level of risk than is currently warranted by 
the data.
There is now a consensus that “attenuated psychosis syndrome” 
is a clinically useful concept, as it identifies help-seeking indi-
viduals in need of intervention, who have elevated risk of 
developing a psychosis spectrum condition in the years following 
ascertainment38. Importantly, the slow “ramp-up” to onset 
of the initial psychotic episode represents both a window of 
vulnerability and an opportunity to intervene. Findings of altered 
trajectories of brain development, proximal to and even prior to 
illness onset, have highlighted the possible role of progressive 
neuromaturational disturbances in the etiology of illness37. 
The field has moved toward a clinical staging model, in which 
Page 5 of 9
F1000Research 2018, 7(F1000 Faculty Rev):1883 Last updated: 03 DEC 2018
the onset of overt psychosis is considered a “late stage” of the 
illness1,30. Current guidelines recommend psychosocially 
focused interventions (cognitive behavioral therapy and family 
intervention)39,40 as a “first line” of treatment in this early stage 
of illness, and antipsychotic medication is recommended only in 
cases of severe and progressive symptomatology41. Currently, 
there is no evidence that any particular intervention in CHR is 
superior to the others; however, there are few long-term outcome 
trials and results are inconsistent. More importantly, there is 
not yet a known mechanism of action for treatments that do 
show efficacy42. Clearly, more work is needed to develop 
effective and efficient evidence-based prevention strategies that 
are based on individual prognosis and risk factors.
The broader psychosis spectrum
In addition to increased focus on clinical ascertainment of at-risk 
individuals, there has been a conceptual “broadening” of the 
psychosis spectrum. Late adolescence to early adulthood repre-
sents a period of elevated risk for schizophrenia and related psy-
chotic spectrum (PS) conditions43,44. In addition to being associated 
with the onset of clinically diagnosed psychotic illness, adoles-
cence is associated with a peak in the emergence of subclinical 
psychotic-like experiences45,46. Unlike the break with external 
reality that defines psychosis, these experiences reflect mild to 
moderate deviations of beliefs and experiences from reality.
Recent evidence from population-based cohorts indicates that 
non-treatment-seeking youth experiencing PS symptoms exhibit 
changes in neural structure and function as well as alterations in 
social and cognitive processing that are qualitatively similar to dif-
ferences observed in schizophrenia but of lesser magnitude47–49. 
In particular, PS youth show lower predicted cognitive age and 
greater developmental lag compared with both typically develop-
ing youth and those with other psychiatric symptoms50, suggest-
ing both possible etiologic overlap with syndromal psychosis 
and some degree of specificity. Furthermore, alterations in 
structural51 and functional47,52 brain connectivity in PS youth seem 
to parallel those observed in established illness. New data from 
a large-scale multisite study of almost 4000 prepubertal youth 
indicate that more severe self-reported childhood psychotic-like 
experiences were associated with neurocognitive deficits, motor 
and speech developmental milestone delays, and family history 
of psychosis. These findings suggest that these symptoms, even 
in young children, are associated with many of the same risk 
factors associated with psychotic symptoms in older individuals, 
further supporting the dimensionality of psychosis across the life 
span53.
Conclusions
The past few years have seen remarkable discoveries regarding 
the genetic basis of schizophrenia. Yet, thus far, these advances 
have not led to new, mechanistically defined treatments for this 
devastating illness. Relatedly, very few biomarkers have been 
successfully implemented in clinical practice54. How do we move 
forward to close the translational gap? Clearly, the complexity of 
schizophrenia’s genetic architecture, involving risk genes rang-
ing from common alleles of small effect to rare alleles of large 
effect, presents major challenges. One key challenge will be 
identifying biological pathways that may converge across this “risk 
continuum”. Recent findings suggest that increased C4A expression 
in individuals with schizophrenia may result in overly aggressive 
synaptic pruning, leading to excessive gray matter loss proximal 
to disease onset. Although this intriguing possibility is unlikely 
to explain all cases of schizophrenia (perhaps not even a substan-
tial percentage) and modification of synaptic pruning may pose 
challenges as a therapeutic target, this may be considered one of 
the first real inroads into the pathobiology of schizophrenia. In 
parallel, early intervention for those at CHR has improved our 
understanding of risk factors prior to overt illness onset and 
supports the efficacy of psychosocial interventions during this 
vulnerable period. As such, these mechanistic and clinically 
oriented approaches have now converged on a focus on early 
development as being critical for both understanding trajectories 
and intervening to change them.
Given the rapidly increasing understanding of the regulation and 
expression of genes and the development of better tools to inves-
tigate molecular and cellular mechanisms in model systems55, 
the hope is that new treatments that can dramatically change the 
course of illness are on the horizon.
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